Key player · Company profile
Eli Lilly and Company
Named as a key player in 264 of our reports, across 33 regions and countries.
Named as a key player in 264 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 8
Brazil 8
Canada 8
China 8
Ecuador 8
Egypt 8
France 8
Germany 8
Hong Kong 8
India 8
Italy 8
Japan 8
Kenya 8
Malaysia 8
Mexico 8
New Zealand 8
Philippines 8
Russia 8
Saudi Arabia 8
Singapore 8
South Africa 8
Spain 8
Thailand 8
UAE 8
UK 8
US 8| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Anti-Depressants Drugs | Pharmaceuticals | $18 Bn | 2.7% |
| Insulin Delivery Devices | Medical Devices | $15.9 Bn | 6.5% |
| Digital Biomarkers | Digital Health | $4.4 Bn | 35.5% |
| Alzheimers Dignostic | Healthcare Services | $2.1 Bn | 6.9% |
| Alopecia areata | Healthcare Services | – | – |
| Alzheimer Drugs | Pharmaceuticals | – | – |
| Antithrombotic Drugs | Pharmaceuticals | – | – |
| Axial Spondyloarthritis (axSpA) | Pharmaceuticals | – | – |
Named as key players in the same markets as Eli Lilly and Company (number of shared markets).
Johnson & Johnson5 shared markets
AbbVie Inc.4 shared markets
Novartis AG4 shared markets
Sanofi4 shared markets
AstraZeneca3 shared markets
F. Hoffmann-La Roche Ltd3 shared markets
GlaxoSmithKline plc3 shared markets
Pfizer Inc.3 shared markets